ABSI News and Press, Absci Corporation From 04/28/22

VANCOUVER, Wash., April 28, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating in the upcoming B...

Absci (NASDAQ:ABSI) said it has opened its Absci AI Research Lab in Manhattan's Plaza District to expand drug discovery capabilities. The lab will help expand Absci's Denovium Engine AI platform and deployment of its machine learning pipeline for predicting therapeutic protein ...

VANCOUVER, Wash. and NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the opening of the Absci AI Research L...

The following slide deck was published by Absci Corporation in conjunction with this event. For further details see: Absci (ABSI) Investor Presentation - Slideshow

Philippe Laffont’s 13F portfolio value decreased from $24.58B to $22.55B this quarter. They increased Tesla and Microsoft while reducing Moderna, Snowflake, DoorDash, Marqeta, and Twilio. They also added Pfizer, Visa, and Applied Materials while dropping UiPath. For f...

Absci press release (NASDAQ:ABSI): FY net loss of $101M Revenue of $4.8M (flat Y/Y). For further details see: Absci reports FY results

VANCOUVER, Wash., March 22, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter and ...

Absci to present in-silico drug discovery technology at NVIDIA GTC Breakthrough ML achievements highlight the viability of the computational lead optimization pipeline Absci collaborates with NVIDIA on research to accelerate and scale in-silico drug discovery platform ...

VANCOUVER, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the appointment of Andreas Busch, PhD, to its Board...

VANCOUVER, Wash., March 16, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a drug and target discovery company harnessing deep learning, AI and synthetic biology to expand the therapeutic potential of proteins, today announced that Absci Lead AI Scientist Joshua Meier will be ...